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Genomic imbalances detected by comparative genomic hybridization are prognostic markers
in invasive ductal breast carcinomas
Aims: The aim of this work is the study of the
prognostic significance of the chromosomal aberrations
described in a series of invasive ductal breast carcin-
omas.
Methods and results: We analysed by comparative
genomic hybridization a group of 70 formalin-fixed
paraffin-embedded invasive ductal breast carcinomas.
Aberrations showed a frequency similar to previous
studies using frozen tumours. Interestingly, we identi-
fied gains involving 6q16-q24 more frequently than in
other series. We analysed the association among the
chromosomal imbalances, 11 histopathological factors,
relapse rate and overall survival of patients. Associa-
tions showed 16q losses as a potential marker of good
prognosis, as they were more frequent in node-negative
(P ¼ 0.025) and in oestrogen-positive tumours (P <
0.001). Furthermore, 100% of bcl-2+ tumours presen-
ted this aberration compared with 29.3% in bcl-2–
(P ¼ 0.014). 1q, 11q, 17q and 20q gains were associ-
ated with poor prognosis: 95% of cases with 1q gains
were bigger than 20 mm (P ¼ 0.041). Tumours with
1q and 11q gains showed a higher relapse rate
(P ¼ 0.063; P ¼ 0.066). Within the good prognosis
group of lymph node-negative patients, 17q and 20q
gains identify a subgroup with increased relapse rate
(P ¼ 0.039).
Conclusions: Chromosomal imbalances, together with
histopathological factors, may help to predict outcome
in breast cancer patients.
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Introduction
Breast cancer is the most frequent type of cancer
among women in western countries.1 Because of its
incidence and complexity, enormous efforts have been
made to increase knowledge about breast cancer
biology and to develop new therapeutic strategies.2
Many new prognostic factors have been suggested, but
the prognostic value of a wide number of them is still
not confirmed. A recent review of prognostic factors
used in breast cancer has considered tumour size, nodal
status, micrometastasis, histological grade and type,
mitotic figure count and hormone receptor status as
the only factors with prognostic value and use in
clinical patient management.3
Genetic studies have contributed to increase the
knowledge of this disease. One of the most useful
genetic techniques to study breast cancer has been
comparative genomic hybridization (CGH). CGH allows
detection of chromosomal imbalances without the need
for tumour metaphases and with the possibility of using
any source of tissue (fresh, frozen or paraffin-embedded
specimens). In breast cancer, the main chromosomal
imbalances detected have been gains on 8q, 1q, 11q,
17q and 20q and losses on 16q, 8p, 13q, 17p and
11q23. 1q gains and 16q losses have been reported to
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be involved in early steps in cancer progression; 8q,
11q, 17q and 20q gains and 13q losses have been
associated with aggressive phenotypes and have al-
lowed the characterization of new genes such as AIB1
(20q13).4–6
Most of the CGH publications have focused on the
description of chromosomal imbalances, but several
studies have also reported the associations between
chromosomal imbalances and clinicopathological prog-
nostic factors in retrospective analysis, using paraffin-
embedded and frozen tissues.5–7 In breast cancer, no
more than three pathological parameters have been
considered. The pathological factor more frequently
studied has been the histological grade.8,9 Oestrogen
receptor expression (ER),10 the value of the mean
nuclear area, the mitotic index and the apoptotic
index6,11 have also been considered. Tirkkonnen et al.
studied 55 unselected breast carcinomas where asso-
ciations with tumour size, nodal status, grade, ER and
progesterone receptor (PR) expression, DNA index and
S-phase fraction were established.5 They found gains of
8q correlated with DNA index and high S-phase
fraction, as well as the association between Xq loss
and oestrogen receptor negativity.
We present the analysis of a homogeneous series of
70 invasive ductal breast carcinomas by CGH. In order
to find genetic aberrations that may be used as
prognostic markers, we associated the chromosomal
imbalances found with 11 histopathological parame-
ters routinely determined in clinical management, the
overall survival and the relapse rate.
Materials and methods
P A T I E N T S
We selected 70 patients diagnosed with invasive ductal
breast carcinoma at the Hospital of Navarra between
1991 and 1994. Pathological characterization of the
samples was done according to the European
Commission Group on Breast Screening Pathology
(ECGBP).12 The mean age of the patients was
62.5 years (range 33–95 years). The mean follow-up
time was 64 months (range 6–103 months). Disease-
free survival and the presence of local, regional and/or
distant metastases were also noted. The 2-year overall
survival of the series was 87% (SD ¼ 4.5%) and 75.9%
within 5 years (SD ¼ 5.8%). The 2-year relapse rate
was 14.6% (SD ¼ 5.1%) and 29.2% (SD ¼ 6.5%)
within 5 years.
P A T H O L O G I C A L F A C T O R S
From each sample tumour size, histological grade,
axillary lymph node status and Nottingham Prognostic
Index were evaluated. Immunohistochemical study of
ER and PR), p53 and Ki67 were made using the
VentanaTM Enhanced DAB Detection Kit. bcl-2 and
ErbB-2 expression were studied by the Super Sensitive
Immunodetection System (Biogenex). More details
about immunohistochemistry methodology are listed
in Table 1. DNA ploidy was analysed by cytometry
after Feulgen staining. In all cases, positive and
negative controls were used. Immunohistochemistry
results were scored semiquantitatively in four grades,
considering levels 0, 1, 2, and 3 according to the
number of positive cells and the intensity of the
staining. In order to facilitate the statistical analysis
we classified the immunohistochemistry results in
positive or negative groups. Table 2 summarizes the
pathological features of the samples analysed.
C O M P A R A T I V E G E N O M I C H Y B R I D I Z A T I O N
Genomic DNA was isolated from archival paraffin
block samples. Prior to DNA extraction, we selected in
each sample the most representative tumour region
according to the adjacent haematoxylin–eosin-stained
Table 1. Immunohistochemical stains
Antibody/antigen Source Dilution Antigen retrieval
Oestrogen receptor ATOM-Ventana Prediluted 10x antigen retrieval Citra solution pressure cooker, 4 min
Progesterone receptor ATOM-Ventana Prediluted 10x antigen retrieval Citra solution pressure cooker, 4 min
p53 ATOM-Ventana Prediluted 10x antigen retrieval Citra solution pressure cooker, 4 min
erbB-2 BioGenex Prediluted 10x antigen retrieval Citra solution pressure cooker, 4 min
bcl-2 BioGenex 1:100 10x antigen retrieval Citra solution pressure cooker, 4 min
Ki67 Dako 1:50 10x antigen retrieval Citra solution pressure cooker, 4 min
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section. In order to obtain a good quality of DNA,
extraction was performed with a protocol slightly
modified from Isola et al.13 Briefly, multiple thin
sections from tissue were digested with proteinase K at
55C during 3–5 days. A commercial DNA purification
kit (QIAamp Tissue Kit; Quiagen, Hilden, Germany)
was used to purify DNA. Direct DNA labelling was
performed using Vysis nick translation kit (Vysis
GmbH, Stuttgart, Germany). Digestion time and
enzyme concentration were adjusted for each sample.
In order to avoid an excessive DNA fragmentation we
reduced DNase and nick translation reaction time to
20 min. The labelling of this DNA was improved by
increasing the DNA polymerase I concentration. In six
cases, preamplification of the DNA using degenerate
oligonucleotide-primed PCR methodology (DOP-PCR)
was necessary.14
Because of the high DNA fragmentation, spectro-
photometry usually overestimates DNA concentration
from paraffin samples. In order to obtain confirmation
we added equal concentrations of both DNAs; sex-
mismatched experiments were used. For each case,
between 8 and 10 metaphases were analysed. Numer-
ical analysis of DNA imbalances was performed using
fixed thresholds: 0.8 for losses and 1.2 for gains.
S T A T I S T I C A L A N A L Y S I S
Statistical analysis was performed with SPSS software
(Windows v. 9.0). Differences in the average of copy
number aberrations among groups characterized by
histopathological factors were analysed with Student’s
t-test, one way analysis of variance or the Mann–
Whitney U-test, and Kruskall–Wallis test depending on
the results of Kolmogorov–Smirnov normality test.
The differences in the frequency of the most common
gains and losses (those present in >15% of cases)
among histopathological groups were analysed by the
v2 contingency test.
The relationship between histopathological factors
and chromosomal aberrations with the overall survival
and the relapse rate was analysed by the Kaplan–Meier
method. The association of the copy number aberrations
to prognosis was analysed by the regression Cox test.
Values of P £ 0.05 were considered to be statistically
significant and 0.05 < P £ 0.1 were considered to be
nearly significant. The size of the different subgroups
and the low number of events prevented multivariate
analysis.
Results
Technically successful results were obtained in 57 out
of 70 tumours (81.4%). CGH detected genetic aberra-
tions in 55/57 tumours (96%). The mean number of
copy number aberrations was 5.8 per tumour (SD ¼
0.45, range 0–15). The number of gains was 3.6
(SD ¼ 0.28, range 0–9) and that of losses 2.2
Table 2. Pathological features of the 57 invasive ductal
breast carcinoma samples analysed by CGH in this study
Pathological factors n %
Tumour size
<20 mm 10 17.5
‡20 mm 47 82.5
Histological grade
I 3 5.3
II 34 59.6
III 20 35.1
Node status
No nodes involved 26 45.6
1–3 nodes involved 16 28.1
4 nodes involved 13 22.8
No data 2 3.5
Oestrogen receptors
Negative 42 73.6
Positive 15 26.4
Progesterone receptors
Negative 37 65
Positive 20 35
p53
Negative 31 54.4
Positive 26 45.6
erbB-2
Negative 31 54.4
Positive 26 45.6
bcl-2
Negative 16 28
Positive 41 72
Ki67
Negative 0 0
Positive 57 100
Ploidy
Diploid 15 26.3
Aneuploid 41 71.9
No data 1 1.8
Nottingham Prognostic Index
Good prognosis 10 17.5
Moderate prognosis 24 42.1
Poor prognosis 21 36.8
No data 2 3.5
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(SD ¼ 0.27, range 0–8). A summary of all chromoso-
mal aberrations detected is shown in Figure 1. Chro-
mosomal changes affected all chromosomes except
chromosome 21. The most frequent gains were on 8q
(63.1%), 17q (45.6%), 1q (38.6%), 20q (26.3%), 11q
(21%) and 6q (17.5%). The most frequent losses
affected at 16q (21%), Xp and Xq (19.3%), 13q
(17.5%), 11q (15.7%) and 8p (15.7%).
It was common that the abnormalities affected entire
chromosomes or chromosomal arms. However, subre-
gional imbalances were detected in 11q (losses at
11q21-qter), 6q (gains at 6q16-q24, 6q16-q22, 6q22-
q24) and 14q (gains at 14q12-q22, 14q11-q24.2,
14q32, 14q14-q24, 14q11-q21). In 11 samples, we
found aberrations limited at one band as gains on
1p21, 7q11, 11q13 and 12q15.
We detected slight differences in the average of
copy number aberrations between histopathological
groups: the average number of gains was higher in
tumours >20 mm relative to those of small size (3.9
versus 2.5; P ¼ 0.058), and in tumours with p53
accumulation (4.2 versus 3.2; P ¼ 0.070). Samples
positive for PR expression showed twice as many
losses as PR-negative samples (P ¼ 0.083). No asso-
ciations were found between either copy number
aberration and survival or copy number aberration
and relapse rate.
We compared the aberrations present in >15% of
cases with 11 pathological factors. We first confirmed
the prognostic value of the histopathological factors:
only the size, the node status and the Nottingham
Prognostic Index showed significant association with
prognosis (Table 3). Chromosomal aberrations found to
be significantly associated with pathological features
are summarized in Table 4. Of tumours with 1q gains,
95% were >20 mm (P ¼ 0.041). Of samples with 6q
Figure 1. Summary of the genetic imbalances detected in 57 invasive ductal carcinomas of the breast. The vertical lines on the right of the
chromosome ideograms represent gains and the vertical lines on the left represent losses.
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gains, 80% showed p53 accumulation (P ¼ 0.016).
16q losses were more frequent in node-negative
tumours (P ¼ 0.025), 46.7% of samples positive for
ER also showed 16q losses (P < 0.001) and 100% of
tumours with this aberration showed a positive bcl-2
over-expression (P ¼ 0.014). 8q gains were more fre-
quent in tumours classified within the poor prognostic
group relative to those of the good prognostic group,
according to the Nottingham Prognostic Index
(81% versus 30%, P ¼ 0.022).
Kaplan–Meier analysis revealed a 5-year relapse rate
of 41.3% for cases with gains on 1q and a rate of
18.5% for cases without 1q gain (P ¼ 0.063). Patients
with 11q gains showed a relapse of 50% compared
with 23.7% in tumours without this imbalance
(P ¼ 0.066). Considering node-negative patients only,
gains on 17q and 20q were significantly associated
with early relapse (P ¼ 0.039) (Figure 2).
Discussion
Cytogenetic retrospective analyses are limited to the
use of formalin-fixed and paraffin-embedded samples.
The quality of the CGH analysis depends largely on
the quality of tumour DNA. Especially when working
with paraffin-embedded samples, high DNA fragmen-
tation and poor labelling efficiency reduce the sensi-
tivity of detection of chromosomal imbalances.13 In
our study, we achieved a good quality labelling by
reducing the concentration of DNase and the diges-
tion time, and increasing concentration of the DNA
polymerase I. According to the literature, CGH
success rates are between 70% and 90%.15 When
paraffin-embedded tissues are used, lower rates are
expected. In our series, with the technical modifica-
tions described, we obtained a high success rate of
81.4%.
Genetic changes identified in this series are similar to
those described in other breast cancer CGH studies
Table 3. Associations between the pathological factors
studied, overall survival and relapse rate
Overall survival
P
Relapse rate
P
Size 0.052 0.051
Grade 0.553 0.561
Node status 0.003 0.001
Oestrogen receptor 0.251 0.302
Progesterone receptor 0.185 0.761
p53 0.792 0.463
erbB-2 0.725 0.145
bcl-2 0.137 0.807
Ki67 0.407 0.431
Ploidy 0.286 0.272
Nottingham Prognostic
Index
0.032 0.069
Table 4. Significant associations between recurrent chromosomal imbalances and pathological factors
Chromosomal imbalances P
Features of good prognosis
Node-negative tumours Losses on 16q and 11q 0.025 and 0.040
Oestrogen receptor-positive Losses on 16q <0.001
bcl-2-positive Losses on 16q 0.014
p53-negative Losses on 11q 0.021
Progesterone receptor-positive Losses on Xq 0.021
Features of poor prognosis
Tumours >20 mm Gains on 1q 0.041
p53-positive Gains on 6q 0.016
Aneuploid tumours Losses on 13q 0.027
High Nottingham Prognostic Index Gains on 8q 0.022
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using mostly frozen tumours5,8,10,11,15,16 (Table 5).
The different frequencies found between these previous
publications and our series for 1q gains and 8p losses
could be due to a slightly lower sensitivity of CGH from
paraffin samples and/or the presence of normal DNA in
tumour samples. Gains on 8q, 1q, 17q, 20q and 11q
and losses on 16q, Xq, 13q, 11q and 8p were the most
frequent imbalances.
Interestingly, we found gains on 6q more frequently
than in other series (Table 5). In these publications
losses on 6q were always more frequent than
gains.5,7,8,10,11,15–17 Only Loveday et al.17 showed
results similar to ours, with 6q gains more frequent
than 6q losses. In our series, gains were limited to
bands 6q16-q24, the minimal region involved being
limited to 6q22-q23. Hermsen et al.11 and Kuukasjarvi
et al.18 showed gains affecting the same bands, more
frequent in aneuploid and bad prognosis tumours.
Confirming our results, a recent allelotyping analysis of
Rodriguez et al.19 showed that the 6q21-q22 region is
most commonly involved in gains, whereas 6q13-q14
and 6q25-q27 are frequently lost. Bands 6q22-q23
harbour the c-MYB gene, and c-Myb expression has
been associated with oestrogen stimulation and the
presence of ER in breast cancer. This gene is amplified
in this neoplasia more frequently in tumours with
BRCA1 mutations than in sporadic tumours.20 In this
regard, 20% of our cases with 6q gains showed a
previous familiar history of breast cancer, although
BRCA1 mutations have not been analysed. FISH
studies analysing MYB amplification and other target
genes in 6q22-q24 are in progress.
A rarely described gain on 14q11-q24 was detected
in our study (minimal region involved 14q13-q21).
The BRF1 gene has been described to be amplified in
this region (14q22-q24) in breast cancer lines.21
Further studies may provide more information about
the genes involved.
This study reports associations between chromoso-
mal imbalances, histopathological parameters, overall
survival rate and relapse rate in a homogeneous series of
breast tumours. Previous CGH studies have considered
only one to three pathological parameters, whereas 11
features were analysed in the present work.
The main associations described in our study concern
16q losses with features of good prognosis and 1q, 8q,
11q, 17q and 20q gains with poor prognosis (Table 4).
16q losses were significantly associated with no lymph
node involvement, ER-positive expression and over-
expression of bcl-2 (Table 4). Axillary lymph node
status is the most important predictor of disease-free
survival and overall survival in breast cancer,3 as we
confirmed in our series (P < 0.001, Table 3). Our series
showed that 52.9% of samples without node involve-
ment have 16q losses versus only 11.1% in node-
positive cases (P ¼ 0.025).
Oestrogen receptor and PR determinations are the
main biological markers routinely used to address breast
cancer therapy.22 In our series, ER and PR-positive
patients showed a better overall survival and lower
relapse rate than those with negative receptors. How-
ever, differences were not significant (i.e. ER-positive
relapse rate was 19.6% compared with 43.3% in ER-
negative tumours, P ¼ 0.302). A likely explanation
could be the high overall survival of our series due to
the fact that most of our patients belong to the Early
Detection Programme developed in Navarra. The few
number of events in each pathological subgroup could
also explain this absence of significance. As previously
reported,10 we detected 16q losses more frequently in
ER-positive tumours than in ER-negative (46.6% versus
11.9%, P < 0.001), confirming its association with
good prognosis.
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bcl-2 expression has been primarily considered as a
predictive marker of response to adjuvant therapy.23
Most reports have also associated the lack of bcl-2
expression with poor survival.3,24 Previously to our
study, bcl-2 expression has been included only once in
CGH publications of breast cancer25 and it has never
been associated with chromosomal imbalances. In our
series, all tumours with bcl-2 over-expression showed
16q losses (P ¼ 0.014).
The association of 16q losses with other prognostic
factors has previously shown the good prognostic value
of this imbalance. Buerguer et al. found a lower fre-
quency of 16q losses in invasive ductal breast carcinoma
of grade III than in invasive ductal breast carcinoma of
grade II and ductal in-situ carcinomas.9,26,27 They also
associated this loss with the absence of necrosis and a
significantly lower mitotic index and apoptotic index. We
also found a higher frequency of 16q losses in grade II
than grade III tumours (66.7% versus 25%), but the
differences were not significant because of the small size
of the subgroups (eight tumours of grade II and three of
grade III). Roylance et al. and Vos et al. found this
aberration more frequently in well-differentiated
tumours.8,28 Molecular genetic studies found a statisti-
cally significant association of LOH at 16q23.2-24.2
with absence of distant metastases, disease-free survival,
and overall survival.29 Our study confirms these results
and shows the association of 16q losses with two of the
most important prognostic factors in breast cancer: node
involvement and ER expression.
In our study, 1q, 8q, 11q, 17q and 20q gains were
significantly associated with poor prognosis (Table 4).
8q gains were more frequent in tumours with poor
clinical outcome (those with a high Nottingham
Prognostic Index) than in those of the good prognosis
group (81% versus 30%, P ¼ 0.022). These results are
in agreement with several CGH studies where 8q gains
were associated with a higher mitotic index, apoptotic
index and mean nuclear area,6,11 poor prognosis in
node-negative patients,7 high DNA index and S-phase
fraction,5 grade III tumours,8 and aneuploidy.30 In our
series, this aberration was also more frequent in
aneuploid tumours (66%) and node-positive tumours
(64%), although without statistical significance
(P ¼ 0.290 and P ¼ 0.072, respectively).
Our results also suggest that gains of 1q and 11q are
associated with poor prognosis. The 5-year relapse rate
was 41.3% for tumours with 1q gains versus 18% for
tumours without this aberration (P ¼ 0.063). Relapse
rate was 50% for tumours with 11q gains compared
with 23.7% for tumours without this imbalance
(P ¼ 0.063). We also found that 95% of tumours
with 1q gains were >20 mm (P ¼ 0.041). Other CGH
publications have correlated 11q13 gains with more
aggressive phenotypes such as hypodiploid tumours,31
intermediate and poorly differentiate tumours9 and poor
prognosis.11 Consistent with these data, over-expression
of genes located in this region (FGF3, FGF4 and cyclin
D1) have been associated with a higher relapse rate in
node-negative and ER-positive patients.32,33
The other associations described in Table 4 may be
interpreted by caution because of the small size of the
subgroups characterized.
Although no node involvement is the main feature of
good prognosis in breast cancer, 30% of node-negative
patients relapse within 10 years, and 30% die because
of the disease.34 The association that we have found
between 17q gains and 20q gains with poor prognosis
in node-negative patients could have clinical impact
because it identifies a subgroup with poor prognosis
(P ¼ 0.039). 17q and 20q gains have been always
associated with more aggressive phenotypes.4,28
Amplifications/over-expression of some genes located
in these regions such as ERBB-2, Topoisomerase IIa
and AIB1 have been described as responsible for this
poor outcome.35–37
In conclusion, we present a series of 57 formalin-
fixed paraffin-embedded breast tumours analysed by
CGH. Successful results were obtained in 81.4% of the
samples. Our results show that, with technical modi-
fications, CGH in paraffin samples should be a useful
tool for retrospective studies using archival material.
These chromosomal imbalances could characterize
new genetic markers of breast tumour progression.
Together with conventional prognostic factors, losses
on 16q and gains on 1q, 8q, 11q, 17q and 20q could
help to identify new patient subgroups with a different
clinical outcome. Further studies will be required to
confirm the prognostic value of these aberrations in
individual tumours and to identify the genes involved.
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